These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 21054179)

  • 1. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
    Felton TW; Baxter C; Moore CB; Roberts SA; Hope WW; Denning DW
    Clin Infect Dis; 2010 Dec; 51(12):1383-91. PubMed ID: 21054179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.
    Chishimba L; Niven RM; Cooley J; Denning DW
    J Asthma; 2012 May; 49(4):423-33. PubMed ID: 22380765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
    Sambatakou H; Dupont B; Lode H; Denning DW
    Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles.
    Koyama K; Ohshima N; Suzuki J; Kawashima M; Takeda K; Ando T; Sato R; Nagai H; Matsui H; Ohta K
    J Infect Chemother; 2014 Jun; 20(6):375-9. PubMed ID: 24679654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria.
    Rodriguez-Goncer I; Harris C; Kosmidis C; Muldoon EG; Newton PJ; Denning DW
    Int J Antimicrob Agents; 2018 Aug; 52(2):258-264. PubMed ID: 29906567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.
    Heinz WJ; Egerer G; Lellek H; Boehme A; Greiner J
    Mycoses; 2013 May; 56(3):304-10. PubMed ID: 23170837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
    Winston DJ; Bartoni K; Territo MC; Schiller GJ
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
    Walsh TJ; Raad I; Patterson TF; Chandrasekar P; Donowitz GR; Graybill R; Greene RE; Hachem R; Hadley S; Herbrecht R; Langston A; Louie A; Ribaud P; Segal BH; Stevens DA; van Burik JA; White CS; Corcoran G; Gogate J; Krishna G; Pedicone L; Hardalo C; Perfect JR
    Clin Infect Dis; 2007 Jan; 44(1):2-12. PubMed ID: 17143808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
    Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
    Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posaconazole: an oral triazole with an extended spectrum of activity.
    Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
    Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
    Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment.
    Hachem RY; Langston AA; Graybill JR; Perfect JR; Pedicone LD; Patino H; Raad II
    J Antimicrob Chemother; 2008 Dec; 62(6):1386-91. PubMed ID: 18835806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and prognosis of chronic pulmonary aspergillosis.
    Ohba H; Miwa S; Shirai M; Kanai M; Eifuku T; Suda T; Hayakawa H; Chida K
    Respir Med; 2012 May; 106(5):724-9. PubMed ID: 22349065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial.
    Cadranel J; Philippe B; Hennequin C; Bergeron A; Bergot E; Bourdin A; Cottin V; Jeanfaivre T; Godet C; Pineau M; Germaud P
    Eur J Clin Microbiol Infect Dis; 2012 Nov; 31(11):3231-9. PubMed ID: 22782438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases].
    Gürcan S; Tikveşli M; Eryildiz C; Evci C; Ener B
    Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis.
    Catanzaro A; Cloud GA; Stevens DA; Levine BE; Williams PL; Johnson RH; Rendon A; Mirels LF; Lutz JE; Holloway M; Galgiani JN
    Clin Infect Dis; 2007 Sep; 45(5):562-8. PubMed ID: 17682989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis.
    Kosmidis C; Rodriguez-Goncer I; Rautemaa-Richardson R; Richardson MD; Moore CB; Denning DW
    J Antimicrob Chemother; 2019 Apr; 74(4):1056-1061. PubMed ID: 30590533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
    Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R
    Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.